257 related articles for article (PubMed ID: 26910291)
21. Cell killing by antibody-drug conjugates.
Kovtun YV; Goldmacher VS
Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
[TBL] [Abstract][Full Text] [Related]
22. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
[TBL] [Abstract][Full Text] [Related]
23. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
24. Tumor specific novel taxoid-monoclonal antibody conjugates.
Wu X; Ojima I
Curr Med Chem; 2004 Feb; 11(4):429-38. PubMed ID: 14965224
[TBL] [Abstract][Full Text] [Related]
25. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
[TBL] [Abstract][Full Text] [Related]
26. Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
Hinrichs MJM; Ryan PM; Zheng B; Afif-Rider S; Yu XQ; Gunsior M; Zhong H; Harper J; Bezabeh B; Vashisht K; Rebelatto M; Reed M; Ryan PC; Breen S; Patel N; Chen C; Masterson L; Tiberghien A; Howard PW; Dimasi N; Dixit R
Clin Cancer Res; 2017 Oct; 23(19):5858-5868. PubMed ID: 28630216
[No Abstract] [Full Text] [Related]
27. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Zammarchi F; Corbett S; Adams L; Tyrer PC; Kiakos K; Janghra N; Marafioti T; Britten CE; Havenith CEG; Chivers S; D'Hooge F; Williams DG; Tiberghien A; Howard PW; Hartley JA; van Berkel PH
Blood; 2018 Mar; 131(10):1094-1105. PubMed ID: 29298756
[TBL] [Abstract][Full Text] [Related]
28. Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells.
Hellmann I; Waldmeier L; Bannwarth-Escher MC; Maslova K; Wolter FI; Grawunder U; Beerli RR
Front Immunol; 2018; 9():2490. PubMed ID: 30450096
[TBL] [Abstract][Full Text] [Related]
29. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
[TBL] [Abstract][Full Text] [Related]
30. Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar.
Zhu Z; Ramakrishnan B; Li J; Wang Y; Feng Y; Prabakaran P; Colantonio S; Dyba MA; Qasba PK; Dimitrov DS
MAbs; 2014; 6(5):1190-200. PubMed ID: 25517304
[TBL] [Abstract][Full Text] [Related]
31. High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1.
Opaliński Ł; Szymczyk J; Szczepara M; Kucińska M; Krowarsch D; Zakrzewska M; Otlewski J
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29748524
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
33. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
34. Enhanced antitumor effect of anti-tissue factor antibody-conjugated epirubicin-incorporating micelles in xenograft models.
Yamamoto Y; Hyodo I; Koga Y; Tsumura R; Sato R; Obonai T; Fuchigami H; Furuya F; Yasunaga M; Harada M; Kato Y; Ohtsu A; Matsumura Y
Cancer Sci; 2015 May; 106(5):627-34. PubMed ID: 25711681
[TBL] [Abstract][Full Text] [Related]
35. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
36. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells.
Chen R; Rajan S; Overstreet MG; Hurt EM; Thomas SB; Muniz-Medina V; Ward C; Sadowska A; Fleming R; Karanth S; Breen S; Zheng B; Wu Y; Iverson WO; Novick S; O'Day T; Shah DP; Dimasi N; Tiberghien AC; Osbourn J; Walker J
Mol Cancer Ther; 2020 Aug; 19(8):1649-1659. PubMed ID: 32404408
[TBL] [Abstract][Full Text] [Related]
38. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
[TBL] [Abstract][Full Text] [Related]
39. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
Sussman D; Smith LM; Anderson ME; Duniho S; Hunter JH; Kostner H; Miyamoto JB; Nesterova A; Westendorf L; Van Epps HA; Whiting N; Benjamin DR
Mol Cancer Ther; 2014 Dec; 13(12):2991-3000. PubMed ID: 25253783
[TBL] [Abstract][Full Text] [Related]
40. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.
Boghaert ER; Khandke K; Sridharan L; Armellino D; Dougher M; Dijoseph JF; Kunz A; Hamann PR; Sridharan A; Jones S; Discafani C; Damle NK
Int J Oncol; 2006 Mar; 28(3):675-84. PubMed ID: 16465373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
